JAMA Network Home
Sign In
Research Letter

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

JAMA Network Open 10.1001/jamanetworkopen.2025.33535

September 24, 2025 at 11:00 AM EDT

Read the full article

This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.

Corresponding Author: Jonathan H. Pelletier, MD, MS, Division of Critical Care Medicine, Department of Pediatrics, Akron Children’s, 214 W Bowery St, Akron, OH 44308 (jpelletier@akronchildrens.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.33535?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092425

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks